Skip to content

Stuart C Sealfon

2 papers in the library · 72 citations · publishing 2003-2009

Papers

Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy.

Molecular pharmacology January 1, 2003 Barbara J Ebersole, Irache Visiers, Harel Weinstein et al. 72 citations

Indole agonists at the human serotonin 5-HT2A receptor achieve differing efficacies through specific hydrogen-bond interactions with serine residues in helices 3 and 5. Serotonin forms hydrogen bonds with Ser3.36 and Ser5.46; methyl-substitution of the cationic primary amine or the backbone N1-amine disrupts these bonds and reduces efficacy. Mutating Ser3.36 to alanine largely eliminates efficacy differences caused by cationic amine substitution, while mutating Ser5.46 to alanine reduces the efficacy loss from N1-amine substitution. Computational modeling shows these interactions shift the agonist's position in the binding pocket, and the indole ring's position correlates with agonist activity. The findings support a mechanism where agonist position, influenced by specific helix interactions, determines receptor activation, likely shared by other class A G-protein coupled receptors.

Psychedelics and schizophrenia.

Trends in neurosciences April 1, 2009 Javier González-Maeso, Stuart C Sealfon

Research on psychedelics like LSD and dissociative drugs such as PCP has converged with studies of schizophrenia, as their effects mimic core symptoms of the disorder. Some atypical antipsychotics were identified by their high affinity for serotonin 5-HT(2A) receptors, the same target as LSD-like drugs. Effects of PCP-like drugs are strongly influenced by modulation of both 5-HT(2A) and metabotropic glutamate 2/3 receptors. A serotonin-glutamate receptor complex in cortical pyramidal neurons may be the target of both psychedelics and certain antipsychotics. Recent findings on receptor, signaling, and circuit mechanisms could unify the serotonin and glutamate neurochemical hypotheses of schizophrenia.